Generate Biomedicines is trading at $14.74, up 5.36%, amid positive biotech-sector sentiment. - No new company-specific announcement was found for October 9; the latest was October 1, when the first patient was dosed in its GB-5267 trial. - The supplied context reports XBI up 2.50%, alongside successful biotech IPOs today, including TRex Bio and Retension Pharmaceuticals. - Broader indices were up less than 0.5%, making sector strength more relevant than broad-market movement.